Moderate to high levels of nuclear GR protein (IHC H-score ≥100) were observed at baseline across all tumor types, especially ovarian cancer (in 100% of patients) and PDAC (96% of patients), making GR protein an unlikely biomarker of response. This evidence concerns the gene NR3C1 and neoplasm.